Interactions between radiation and endocrine therapy in breast cancer

Endocrine-Related Cancer

Volumn 10, Issue 3, 2003, Pages 375-388

  Schmidberger, H ^a   Hermann, R M ^a   Hess, C F ^a   Emons, G ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; EPIRUBICIN; ESTRADIOL; ESTROGEN; FLUOROURACIL; FULVESTRANT; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CARCINOMA IN SITU; CROSS REACTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; IONIZING RADIATION; RADIOSENSITIVITY; RETROSPECTIVE STUDY; REVIEW;

EID: 0142043469     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0100375     Document Type: Review

References (76)

1. Abraham RT 2001 Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes and Development 15 2177-2199.
2. Albain KS, Green SJ, Ravdin PM, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Schneider DJ, Abeloff MD, Norton L, Henderson IC, Lew D, Livingston RB, Martino S & Osborne CK 2002 Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proceedings of the American Society of Clinical Oncology 21 37a.
3. Banin S, Moyal L, Shieh S-Y, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y & Ziv Y 1998 Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281 1674-1677.
4. Bentzen SM, Skoczylas JZ, Overgaard M & Overgaard J 1996 Radiotherapy-related lung fibrosis enhanced by tamoxifen. Journal of the National Cancer Institute 88 918-922.
5. Böhning K, Busch M, Rave-Fränk M & Dühmke E 1996 Effect of tamoxifen and estrogen treatment on the radiosensitivity of MCF-7 breast cancer cells. Onkologie 19 163-169.
6. Budtz PE 1999 Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen. Cell Proliferation 32 289-302.
7. Canman CE, Lim D-S, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB & Siliciano JD 1998 Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281 1677-1679.
8. Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. PNAS 97 9042-9046.
9. Carney JP, Maser RS, Olivares H, Davis EM, Le Beau M, Yates JR III, Hays L, Morgan WF & Petrini JHJ 1998 The hMre11/hRad 50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 93 477-486.
10. Carroll JS, Prall OW, Musgrove EA & Sutherland RL 2000 A pure estrogen antagonist inhibits cyclinE-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. Journal of Biological Chemistry 275 38221-38229.
11. Chan TA, Hermeking H, Lengauer C, Kinzler KW & Vogelstein B 1999 14-13-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 401 616-620.
12. Dalberg K, Johansson H, Johansson U & Rutqvist LE 1998 A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Cancer 82 2204-2211.
13. Deng C, Zhang P, Harper JW, Elledge SJ & Leder PJ 1995 Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82 675-680.
14. Falck J, Mailand N, Syljuasen RG, Bartek J & Lukas J 2001 The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410 842-847.
15. Falck J, Petrini JHJ, Williams BR, Lukas J & Bartek J 2002 The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nature Genetics 30 290-294.
16. Feigelson HS, Ross RK, Yu MC, Coetzee GA, Reichardt JK & Henderson BE 1996 Genetic susceptibility to cancer from exogenous and endogenous exposures. Journal of Cellular Biochemistry 25 (Suppl) 15-22.
17. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J & Lickley HL 1996 Five versus more than five years of tamoxifen therapy or breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Journal of the National Cancer Institute 88 1529-1542.
18. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L & Oishi RH 1999 Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353 1993-2000.
19. Fisher B, Jeong J-H, Dignan J, Anderson S, Mamounas E, Wickerham D L & Wolmark N 2001 Findings from recent National Surgical Adjuvant Breast and Bowel project adjuvant studies in stage I breast cancer. Journal of the National Cancer Institute Monographs 30 62-66.
20. Fisher B, Bryant J, Dignan JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM & Wolmark N 2002 Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. Journal of Clinical Oncology 20 4141-4149.
21. Foster JS & Wimalasena J 1996 Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Molecular Endocinology 10 488-498.
22. Foster JS, Henley DC, Ahamed S & Wimalasena J 2001a Estrogens and cell-cycle regulation in breast cancer. Trends in Endocrinology and Metabolism 12 320-327.
23. Foster JS, Henley DC, Bukovsky A, Seth P & Wimalasena J 2001b Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Molecular and Cellular Biology 21 794-810.
24. Fowble B, Fein DA, Hanlon AL, Eisenberg BL, Hoffman JP, Sigurdson ER, Daly MB & Goldstein LJ 1996 The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. International Journal of Radiation Oncology-Biology-Physics 35 669-677.
25. Gu W & Roeder RG 1997 Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90 595-606.
26. Hall M & McDonnell DP 1999 The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140 5566-5578.
27. Hellman S 2001 Principles of cancer management: radiation therapy, biologic considerations. In Cancer, Principles and Practice of Oncology, edn 6, pp 270-281. Eds VT DeVita, S Hellman & S Rosenberg. Philadelphia: Lippincott Williams & Wilkins.
28. Hirao A, Kong Y-Y, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ & Mak TW 2000 DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287 1824-1827.
29. Inano H, Onoda M, Suzuki K, Kobayashi H & Wakabayashi K 2002 Prevention of radiation induced mammary tumours in rats by combined use of WR-2721 and tamoxifen. International Journal of Radiation Biology 76 1113-1120.
30. Kantorowitz DA, Thompson HJ & Furmanski P 1993 Effect of conjoint administration of tamoxifen and high-dose radiation on the development of mammary carcinoma. International Journal of Radiation Oncology-Biology-Physics 26 89-94.
31. Kastan MB 2001 Checking two steps. Nature 410 766-767.
32. Kastan MB, Lim D-S, Kim S-T & Yang D 2001 ATM - a key determinant of multiple cellular responses to irradiation. Acta Oncologica 40 686-688.
33. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S & Gustafsson J-A 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138 863-870.
34. Kuiper GGJM, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B & Gustafsson J-A 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139 4252-4263.
35. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM & Webb P 2000 Estrogen receptor pathways to AP-1. Journal of Steroid Biochemistry and Molecular Biology 74 311-317.
36. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A & Harlow E 1997 New functional activities for the p21 family of CDK inhibitors. Genes and Development 11 847-862.
37. Lavin MF & Shiloh Y 1997 The genetic defect in ataxia telangiectasia. Annual Review of Immunology 15 177-202.
38. Lemon HM, Kumar PF, Peterson C, Rodriguez-Sierra JF & Abbo KM 1989 Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen. Cancer 63 1685-1692.
39. Lim D-S, Kim S-T, Xu B, Maser RS, Lin J, Petrini JHJ & Kastan MB 2000 ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 404 613-617.
40. Liu Q, Guntuku S, Cui X, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA & Elledge SJ 2000 Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/ M DNA damage checkpoint. Genes and Development 14 1448-1459.
41. Lowndes NF & Murguia JR 2000 Sensing and responding to DNA damage. Current Opinions in Genetics and Development 10 17-25.
42. McGee MM, Hyland E, Campiani G, Ramunno A, Nacci V & Zisterer DM 2002 Caspase-3 is not essential for DNA fragmentation in MCF-7 cells during apoptosis induced by the pyrrolo-1,5-benzoxazepine, PBOX-6. FEBS Letters 515 66-70.
43. Matsuoka S, Huang M & Elledge SJ 1998 Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282 1893-1897.
44. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K & Elledge SJ 2000 Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. PNAS 97 10389-10394.
45. Maya R, Balass M, Kim S-T, Shkedy D, Leal J-FM, Shifman O, Moas M, Buschmann T, Ronai Z, Shiloh Y, Kastan MB, Katzir E & Oren M 2001 ATM-dependent phophorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes and Development 15 1067-1077.
46. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J & Fan Z 2000 In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clinical Cancer Research 6 701-708.
47. Newton CJ, Schlatterer K, Stalla GK, von Angerer E & Wowra B 1998 Pharmacological enhancement of radiosurgery response: studies on an in vitro model system. Journal of Radiosurgery 1 51-56.
48. Osborne CK 1998 Steroid homone receptors in breast cancer management. Breast Cancer Research and Treatment 51 227-238.
49. Paques F & Haber JE 1999 Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiology and Molecular Biology Reviews 63 349-404.
50. Paulsen GH, Strickert T, Marthinsen AB & Lundgren S 1996 Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. Acta Oncologica 35 1011-1019.
51. Pico C, Martin M, Jara C, Barnadas A, Pelegri A, Balil A, Camps C, Frau A, Rodriguez-Lescure A, Lopez-Vega JM, de la Haba J, Tres A, Alvarez I, Alba E, Arcusa A, Oltra A, Batista N, Checa T, Perez-Carrion R & Campbell J 2002 Epirubicin-cyclophosphamide (EC) chemotherapy plus tamoxifen (T) administered concurrent (Con) versus sequential (Sec): randomized phase III trial in postmenopausal node-positive breast cancer (BC) patients. GEICAM 9401 study. Proceedings of the American Society of Clinical Oncology 21 37a.
52. Piwnica-Worms H 1999 Fools rush in. Nature 401 535-536.
53. Planas-Silva MD & Weinberg RA 1997 Estrogen-dependent cyclinE-Cdk2 activation through p21 redistribution. Molecular and Cellular Biology 17 4788-4792.
54. Prall OWJ, Rogan EM & Sutherland RL 1998 Estrogen regulation of cell cycle progression in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 65 169-174.
55. Rupnow BA, Murtha AD, Alarcon RM, Giaccia AJ & Knox SJ 1998 Direct evidence that apoptosis enhances tumor response to fractionated radiotherapy. Cancer Research 58 1779-1784.
56. Sarkaria JN, Miller EM, Parker CJ, Jordan VG & Mulcahy RT 1994 4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro. Breast Cancer Research and Treatment 30 159-165.
57. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G & Parmar M 1999 Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomized multicentre trial. Radiotherapy and Oncology 52 137-148.
58. Schmidt-Ullrich RK, Valerie K, Fogleman PB & Walters J 1996 Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiation Research 145 81-85.
59. Schmidt-Ullrich, Dent P, Grant S, Mikkelsen RB & Valerie K 2000 Signal transduction and cellular radiation responses. Radiation Research 153 245-257.
60. Shinomiya N 2001 New concepts in radiation-induced apoptosis: 'premitotic apoptosis' and 'postmitotic apoptosis'. Journal of Cellular and Molecular Medicine 5 240-253.
61. Sun Z, Bemer HS, Risberg B, Karlsson MG & Nesland JM 2001 Estrogen receptor-α and C-ERBB-4 expression in breast carcinomas. Virchows Archiv 439 62-69.
62. Sutherland RL, Reddel RR & Green MD 1983 Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. European Journal of Cancer Clinical Oncology 19 307-318.
63. Tanino H, Kubota T, Saikawa Y, Kuo, TH, Takeuchi T, Kase S, Furukawa T, Kitajima M, Sakurai T, Naito Y & Hoffmann RM 1993 Different chemo- and endocrino-sensitivity of MCF-7 cells with or without estradiol supplement in vitro. Anticancer Research 13 1219-1222.
64. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M & Haupt Y 1999 Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO Journal 18 1805-1814.
65. Villalobos M, Aranda M, Nunez MI, Becerra D, Olea N, Ruiz de Almovar M & Pedraza V 1995 Interaction between ionizing radiation, estrogens and antiestrogens in the modification of tumor microenvironment in estrogen dependent multicellular spheroids. Acta Oncologica 34 413-417.
66. Villalobos M, Becerra D, Nunez MI, Valenzuela MT, Shiles E, Olea N, Pedraza V & Ruiz de Almodovar JM 1996 Radiosensitivity of human breast cancer cell lines of different hormonal responsiveness. Modulatory effects of oestradiol. International Journal of Radiation Biology 70 161-169.
67. Wazer DE, Tercilla OF, Lin PS & Schmidt-Ullrich RK 1989 Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17β-estradiol and tamoxifen. British Journal of Radiology 62 1079-1083.
68. Wazer DE, Joyce M, Solares G & Schmidt-Ullrich R 1991 Proliferative inhibition of human breast carcinoma cells by high concentration estradiol does not alter radiosensitivity. Breast Cancer Research and Treatment 18 141-148.
69. Wazer DE, Joyce M, Chan W, Gewirtz D, Lin PS, Solares G & Schmidt-Ullrich RK 1993 Effects of tamoxifen on the radiosensitivity of hormonally responsive and unresponsive breast carcinoma cells. Radiation Oncology Investigations 1 20-28.
70. Wazer DE, Morr J, Erban JK, Schmid CH, Ruthazer R & Schmidt-Ullrich RK 1997 The effects of postradiation treatment with tamoxifen on local control and cosmetic outcome in conservatively treated breast. Cancer 80 732-740.
71. Wollenhaupt K, Kettler A, Brussow KP, Schneider F, Kanitz W & Einspanier R 2001 Regulation of the expression and bioactivation of the epidermal growth factor receptor system by estradiol in pig oviduct and endometrium. Reproduction, Fertility and Development 13 167-176.
72. Wollman R, Yahalom J, Maxy R, Pinto J & Fuks Z 1994 Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. International Journal of Radiation Oncology-Biology-Physics 30 91-98.
73. Wu X, Ranganathan V, Weisman DS, Heine WF, Ciccone DN, O'Neill TB, Crick KE, Pierce KA, Lane WS, Rathbun G, Livingston DM & Weaver DT 2000 ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature 405 477-482.
74. Xu B, Kim S-T & Kastan MB 2001 Involvement of BRCA1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Molecular and Cellular Biology 21 3445-3450.
75. Xu B, Kim S-T, Lim D-S & Kastan MB 2002 Two molecularly distinct G2/ M checkpoints are induced by ionizing irradiation. Molecular and Cellular Biology 22 1049-1059.
76. Zou L & Stillman B 2000 Assembly of a complex containing Cdc45p, replication protein A, and Mcm2p at replication origins controlled by S-phase cyclin-dependent kinases and Cdc7p-Dbf4p kinase. Molecular and Cellular Biology 20 3086-3096.